Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646909 | 0.87 | KIF11 (0.60) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL646467 | 0.85 | KIF11 (0.58) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL645078 | 0.84 | KIF11 (0.70) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL647715 | 0.84 | KIF11 (0.58) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL647060 | 0.84 | KIF11 (0.57) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL647423 | 0.83 | KIF11 (0.68) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL647708 | 0.83 | KIF11 (0.62) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL644308 | 0.83 | KIF11 (0.62) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL644687 | 0.82 | KIF11 (0.61) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL645623 | 0.82 | KIF11 (0.61) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-7919524-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230550-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KIF11 824/4885KCNH2 2582/4885TRPA1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.